Ivermectin and Hydroxychloroquine for Chemo-Prophylaxis of COVID-19: A Questionnaire Survey of Perception and Prescribing Practice of Physicians vis-a-vis Outcomes

Samajdar et al., Journal of the Association of Physicians India, 69:11, Nov 2021

Source

PDF

All
Studies

Meta
Analysis

https://c19early.org/samajdar.html

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 106 studies, recognized in 24 countries.

Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

6,200+ studies for 180+ treatments. c19early.org

Physician survey in India with 164 ivermectin prophylaxis, 129 HCQ prophylaxis, and 81 control patients, showing significantly lower COVID-19 cases with treatment. Details of the treatment and control groups and the definition of cases are not provided, and the results are subject to survey bias. Authors also report on community prophylaxis but present only combined ivermectin/HCQ results.

This is the 67th of 106 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001.

53 studies are RCTs, which show efficacy with p=0.000000087.

This study is excluded in the after exclusion results of meta analysis: minimal details provided; unadjusted results with no group details; results may be significantly affected by survey bias.

Important missing comments or errors? Let us know.

Study covers HCQ and ivermectin.

risk of case, 79.8% lower, RR 0.20, p < 0.001, treatment 12 of 164 (7.3%), control 29 of 81 (35.8%), NNT 3.5, odds ratio converted to relative risk, physician survey.

risk of case, 48.6% lower, RR 0.51, p = 0.03, treatment 11 of 109 (10.1%), control 39 of 200 (19.5%), NNT 11, odds ratio converted to relative risk, combined ivermectin or HCQ in community.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Samajdar et al., 17 Nov 2021, retrospective, India, peer-reviewed, 9 authors, study period 1 September, 2020 - 31 December, 2020, dosage not specified.

This Paper Ivermectin All

Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0